Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the target of a large increase in short interest in July. As of July 31st, there was short interest totaling 61,079 shares, an increase of 152.8% from the July 15th total of 24,157 shares. Based on an average daily volume of 359,826 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.5% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. grew its stake in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera makes up about 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest position. Rosalind Advisors Inc. owned about 9.63% of Biofrontera worth $695,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BFRI. Wall Street Zen upgraded Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Biofrontera Trading Up 3.2%

Shares of BFRI opened at $1.30 on Friday. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.40. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20. The company’s fifty day moving average is $1.08 and its 200 day moving average is $0.98. The stock has a market capitalization of $16.64 million, a PE ratio of -2.89 and a beta of 0.78.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 155.98%. The business had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $9.50 million. Sell-side analysts expect that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.